This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of -33.33% and -16.06%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis Pharmaceuticals (IONS) Down 20.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech Stock Roundup: REGN Cocktail Data Positive, INCY's Jakafi Disappoints & More
by Zacks Equity Research
The biotech sector was in focus last week with vaccine and antibody updates from quite a few companies like Regeneron (REGN) and Incyte (INCY).
Roche (RHHBY) Stops Dosing in Huntington's Disease Study
by Zacks Equity Research
Roche (RHHBY) halts dosing in the phase III GENERATION HD1 study evaluating tominersen in manifest Huntington's disease following recommendation from an iDMC.
Ionis (IONS) Crashes as Roche-Partnered Huntington's Drug Fails
by Zacks Equity Research
Ionis (IONS) stock sinks as partner Roche stops dosing in a late-stage study on tominersen in Huntington's disease.
Ionis (IONS) Q4 Earnings Decline Y/Y, Sales Beat Estimates
by Zacks Equity Research
Ionis (IONS) Q4 adjusted earnings decline year over year. The company issues guidance for 2021.
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of -1116.67% and 9.05%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for February 8th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Why Is Ionis Pharmaceuticals (IONS) Up 4.6% Since Last Earnings Report?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ionis (IONS) Misses Estimates for Q3 Earnings and Sales
by Zacks Equity Research
Ionis (IONS) posts wider-than-expected Q3 loss. Sales miss estimates.
Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of -144.44% and -15.49%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis' Alexander Disease Candidate Gets Orphan Drug Status
by Zacks Equity Research
The FDA assigns an orphan drug designation to Ionis' (IONS) pipeline candidate ION373 for treating patients with Alexander disease.
Alexion & Caelum Begin Studies on CAEL-101 in AL Amyloidosis
by Zacks Equity Research
Alexion (ALXN) and partner Caelum Biosciences begin phase III studies on CAEL-101 in AL amyloidosis.
Why Is Ionis Pharmaceuticals (IONS) Down 2.2% Since Last Earnings Report?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ionis to Acquire Remaining Stake in Akcea, Stocks Rally
by Zacks Equity Research
Ionis (IONS) is set to acquire the remaining 24% stake in Akcea Therapeutics (AKCA) in an all-cash deal.
Ionis (IONS) Q2 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Ionis (IONS) posts narrower-than-expected Q2 loss. Sales miss estimates.
Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 17.86% and -3.17%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akcea (AKCA) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with its pipeline progress, when Akcea (AKCA) reports Q2 results.
Biogen to Pit Spinraza Against Novartis' Zolgensma in Phase IV
by Zacks Equity Research
Biogen (BIIB) intends to start a phase IV study for the assessment of Spinraza's safety in infants and children with SMA who showed a suboptimal clinical response to Novartis' Zolgensma.
USANA (USNA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
USANA (USNA) will release second-quarter 2020 results, which are likely to reflect impacts of the COVID-19 pandemic.
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 9.09% and -16.90%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?